地特胰岛素在妊娠合并糖尿病治疗中的疗效和安全性评价(1)
[摘要] 目的 分析地特胰岛素在妊娠合并糖尿病治疗中的临床疗效和安全性，探讨地特胰岛素在妊娠合并糖尿病治疗中的应用价值。方法 抽取2017年7月—2019年7月期间于该院就诊的80例妊娠合并糖尿病患者为该次研究对象，随机将其分为对照组与研究组，每组40例，对照组患者实施生物合成人胰岛素治疗方案，研究组实施地特胰岛素治疗方案，观察两组患者治疗前后血糖水平、不良反应发生情况以及妊娠结局，并对数据进行分析统计。结果 分析后显示，两组患者治疗前空腹血糖、餐后2 h血糖差异无统计学意义(P>0.05)，治疗后两组空腹血糖、餐后2 h血糖均有所下降，但研究组明显较低于对照组(P<0.05)，研究组不良反应发生率明显低于对照组(P<0.05)，且研究组不良妊娠结局发生率低于对照组(P<0.05)。结论 针对妊娠期糖尿病患者采用地特胰岛素治疗方案疗效更佳，可有效降低血糖水平，并改善妊娠结局，且具有较高的临床用药安全性。
[关键词] 妊娠合并糖尿病;地特胰岛素;生物合成人胰岛素;疗效;安全性
[中图分类号] R4 [文献标识码] A [文章编号] 1672-4062(2020)06(a)-0031-03
[Abstract] Objective To analyze the clinical efficacy and safety of insulin detemir in the treatment of pregnancy complicated with diabetes， and to explore the application value of insulin detemir in the treatment of pregnancy complicated with diabetes. Methods From July 2017 to July 2019， 80 pregnant patients with diabetes mellitus who were treated in the hospital were selected as the research object. They were randomly divided into a control group and a research group， 40 cases in each group. Synthesized human insulin treatment plan， the study group implemented the insulin detemir treatment plan， observed the blood glucose levels， side effects and pregnancy outcomes of the two groups of patients before and after treatment， and analyzed the statistics. Results analysis showed that there was no statistically significant difference in fasting blood glucose before treatment and 2 h postprandial blood glucose between the two groups of patients(P>0.05). After treatment， fasting blood glucose and 2 h postprandial blood glucose decreased in both groups， but the research group was significantly lower than the control group(P<0.05)， the incidence of side effects in the study group was significantly lower than that in the control group(P<0.05)， and the incidence of adverse pregnancy outcomes in the study group was lower than that in the control group(P<0.05). Conclusion The treatment with insulin detemir for gestational diabetes patients is more effective， can effectively reduce blood glucose levels， improve pregnancy outcomes， and has a higher clinical drug safety.
[Key words] Pregnancy with diabetes; Insulin detemir; Biosynthetic human insulin; Efficacy; Safety
妊娠合并糖尿病有“糖尿病合并妊娠(PG-DM)”和“妊娠期糖尿病(GDM)”兩种情况，其中以妊娠期糖尿病居多，约占妊娠80%以上，糖尿病合并妊娠者不足20%[1]。近年来，妊娠合并糖尿病患病率呈逐年上升趋势，妊娠期糖尿病患者糖代谢多数于产后即可恢复正常，但将来患2型糖尿病的概率明显高于正常人，妊娠合并糖尿病可能导致患者并发妊高症，并导致婴儿先天畸形、胎儿早产等严重不良后果，严重威胁母婴生命安全，妊娠期高血糖与妊娠结局有着密切关系，对血糖进行严格控制可改善不良妊娠结局[2]。对于降糖药物和一般治疗血糖控制不佳的患者应早期给予胰岛素治疗[3]。该研究选取2017年7月—2019年7月该院收治的80例妊娠合并糖尿病患者为研究对象，将地特胰岛素应用到妊娠合并糖尿病患者中，取得了较好成效，现将其临床疗效及安全性进行分析，现报道如下。, 百拇医药(张子立)
[关键词] 妊娠合并糖尿病;地特胰岛素;生物合成人胰岛素;疗效;安全性
[中图分类号] R4 [文献标识码] A [文章编号] 1672-4062(2020)06(a)-0031-03
[Abstract] Objective To analyze the clinical efficacy and safety of insulin detemir in the treatment of pregnancy complicated with diabetes， and to explore the application value of insulin detemir in the treatment of pregnancy complicated with diabetes. Methods From July 2017 to July 2019， 80 pregnant patients with diabetes mellitus who were treated in the hospital were selected as the research object. They were randomly divided into a control group and a research group， 40 cases in each group. Synthesized human insulin treatment plan， the study group implemented the insulin detemir treatment plan， observed the blood glucose levels， side effects and pregnancy outcomes of the two groups of patients before and after treatment， and analyzed the statistics. Results analysis showed that there was no statistically significant difference in fasting blood glucose before treatment and 2 h postprandial blood glucose between the two groups of patients(P>0.05). After treatment， fasting blood glucose and 2 h postprandial blood glucose decreased in both groups， but the research group was significantly lower than the control group(P<0.05)， the incidence of side effects in the study group was significantly lower than that in the control group(P<0.05)， and the incidence of adverse pregnancy outcomes in the study group was lower than that in the control group(P<0.05). Conclusion The treatment with insulin detemir for gestational diabetes patients is more effective， can effectively reduce blood glucose levels， improve pregnancy outcomes， and has a higher clinical drug safety.
[Key words] Pregnancy with diabetes; Insulin detemir; Biosynthetic human insulin; Efficacy; Safety
妊娠合并糖尿病有“糖尿病合并妊娠(PG-DM)”和“妊娠期糖尿病(GDM)”兩种情况，其中以妊娠期糖尿病居多，约占妊娠80%以上，糖尿病合并妊娠者不足20%[1]。近年来，妊娠合并糖尿病患病率呈逐年上升趋势，妊娠期糖尿病患者糖代谢多数于产后即可恢复正常，但将来患2型糖尿病的概率明显高于正常人，妊娠合并糖尿病可能导致患者并发妊高症，并导致婴儿先天畸形、胎儿早产等严重不良后果，严重威胁母婴生命安全，妊娠期高血糖与妊娠结局有着密切关系，对血糖进行严格控制可改善不良妊娠结局[2]。对于降糖药物和一般治疗血糖控制不佳的患者应早期给予胰岛素治疗[3]。该研究选取2017年7月—2019年7月该院收治的80例妊娠合并糖尿病患者为研究对象，将地特胰岛素应用到妊娠合并糖尿病患者中，取得了较好成效，现将其临床疗效及安全性进行分析，现报道如下。, 百拇医药(张子立)